Micromatricial Metronidazole Benzoate Film as a Local Mucoadhesive Delivery System for Treatment of Periodontal Diseases by Amal Hassan El-kamel et al.
Micromatricial Metronidazole Benzoate Film as a Local Mucoadhesive
Delivery System for Treatment of Periodontal Diseases
Submitted: February 21, 2007; Accepted: April 19, 2007; Published: September 14, 2007
Amal Hassan El-Kamel,
1 Lubna Y. Ashri,
1 and Ibrahim A. Alsarra
1
1Department of Pharmaceutics, Faculty of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia
ABSTRACT
The main objective of this study was to develop a local,
oral mucoadhesive metronidazole benzoate (MET) delivery
system that can be applied and removed by the patient for
the treatment of periodontal diseases. Mucoadhesive micro-
matricial chitosan/poly(ε-caprolactone) (CH/PCL) films
and chitosan films were prepared. Thermal behavior,
morphology, and particle size measurements were used to
evaluate the prepared films. The effect of different molar
masses of CH and different ratios of medium Mwt molar
mass chitosan (MCH):PCL on water absorption, in vitro
bioadhesion, mechanical properties, and in vitro drug
release was examined. In vivo performance of the selected
formulation was also evaluated. Differential scanning
calorimetry examination revealed that MET existed mainly
in amorphous form. Under microscopic examination, PCL
microparticles were homogeneously dispersed in the films.
The use of different molar masses of CH and different
ratios of (MCH):PCL affected the size of the entrapped
particles. Addition of PCL significantly decreased percent-
age water uptake and bioadhesion force compared with
pure CH film. With regard to mechanical properties, the 2-
layered film containing 1:0.625 MCH:PCL had the best
tensile properties. At fixed CH:PCL ratio (1:1.25), the
slowest drug release was obtained from films containing
high molar mass CH. On the other hand, the 2-layered film
that consisted of 1:0.625 MCH:PCL had the slowest MET
release. In vivo evaluation of the selected film revealed that
metronidazole concentration in saliva over 6 hours ranged
from 5 to 15 μg/mL, which was within and higher than the
reported range of minimum inhibitory concentration for
metronidazole. A significant in vitro/in vivo correlation
under the adopted experimental conditions was obtained.
KEYWORDS: Metronidazole benzoate, chitosan, poly(ε-
caprolactone), periodontal, mucoadhesive, correlationR
INTRODUCTION
Periodontal diseases are localized infections and inflammatory
conditions that are associated with anaerobic Gram-negative
bacteria
1 and affect teeth-supporting structures.
2 The aim of
current periodontal therapy is to remove the bacterial depos-
its from the tooth surface and to shift the pathogenic micro-
biotatoonecompatiblewithperiodontalhealth.
3 Therapeutic
approaches include surgical techniques and mechanical de-
bridementof the rootsurfacesand/or treatment ofthe infection
with systemic or local antibiotics.
4 Local delivery of antimi-
crobial agents is becoming more prevalent since it leads to
higher concentration of the drug at the intended site of action
using a lower dose with an associated reduction in side effects
relative to systemic administration. Mucoadhesive tablets,
2
dentifrices, mouth rinses, dental gels, fibers, compacts, injec-
table semisolidsystems,
3 irrigation devices,
5 films,
6 inserts,
7
and microspheres
8 are local delivery systems that have been
tried in the treatment of periodontal diseases. The application
and removal of these delivery systems may require surgery
proceduresand,sometimes, the incisionsaresupportedbythe
use of cyanoacrylate glue.
Metronidazole is a front-line chemotherapeutic agent for treat-
ing infections by anaerobic bacteria such as Porphyromonas
gingivalis because of the low minimum inhibitory concen-
tration (MIC) required.
9
Chitosan has some antibacterial activities,
10 and it is a prom-
ising bioadhesive material at physiological pHs. However,
adhesion failure may occur when overhydration converts the
chitosan gel network to slippery mucilage.
11 Therefore, addi-
tion of other types of biodegradable polymers in the delivery
system may provide some control over the swelling of chi-
tosan and thereby prevent adhesion failure. Biodegradable
polymers are biocompatible, are easy to formulate into differ-
ent devices, and have good mechanical properties.
11
The main objective of this study was to develop a local, oral,
mucoadhesive, controlled-release metronidazole benzoate
(MET)deliverysystem thatcan be applied tothe buccalmucosa
and removed by the patient for the treatment of periodontal
diseases. To reach this objective, mucoadhesive micromatri-
cial chitosan/poly(ε-caprolactone) (CH/PCL) films and muco-
adhesive chitosan films were prepared. The influence of
formulation parameters on the physicochemical properties
of the prepared films and release characteristics of METwas
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MATERIALS AND METHODS
The different grades of chitosan used in this study were pur-
chased from Aldrich (St Louis, MO) and include low molar
mass CH (LCH) (viscosity, 275.9 cps; degree of deacetylation
[dd], 80.5%), medium molar mass CH (MCH) (viscosity,
755.8 cps; dd, 76.58%), and high molar mass CH (HCH)
(viscosity, 2064 cps; dd, 70.3%). The viscosity of 1% solution
CH in 1% acetic acid was measured by a Brookfield viscom-
eter (Brookfield Engineering Laboratories, Inc., Middleboro,
MA) as stated by the manufacturer. PCL was purchased from
Absorbable Polymers International (Pelham, AL) with inher-
ent viscosity of 1.24 dL/g. METwas provided by Alexandria
Pharmaceuticals(Alexandria,Egypt).Allreagentsandchem-
icals used for chromatography were of high-performance liq-
uid chromatography (HPLC) grade. All other chemicals and
organic solvents were of reagent grade.
Preparation of Micromatricial Chitosan/Poly
(ε-caprolactone) Films
CH/PCL films containing MET were prepared by the emul-
sification/casting/solvent evaporation technique.
11 In this
technique, PCL and MET were dissolved in 3.2 mL of di-
chloromethane. This organic phase was emulsified into an
aqueous phase using an Ultra Turrax homogenizer IKA
model no. T18 basic (IKAWorks Inc., Wilmington, NC) at
10 000 rpm. The aqueous phase was composed of 0.2 g CH
dissolved in 15mL 1%vol/volaceticacid andcontained 4%
wt/wt glycerine as a plasticizer and 0.2% wt/wt Tween 80 as
an emulsifier. The formed oil in water (o/w) emulsion was
cast into Teflon plates with a diameter of 6.3 cm and left to
d r yi na no v e na t3 7 -C±0 . 5 -C overnight. Complete drying
andsolvent evaporation were ensured by thermogravimetric
analysis(TGA). Microparticleswere formed by evaporation
of dichloromethane and precipitation of PCL. The amount of
MET was 0.24 g per plate in all formulations. The composi-
tion of various prepared formulations is shown in Table 1. In
the case of the 2-layered film, a second layer of 2% wt/vol
pure MCH solution in 10 mL of 1% vol/vol acetic acid was
cast on the surface of the 1:0.625 wt/wt MCH:PCL film be-
fore it dried completely.
Preparation of Chitosan and Poly(ε-caprolactone) Films
Chitosan (0.2 g) was dissolved in 15 mL 1% vol/vol acetic
acid containing 4% glycerine. For MCH films containing drug,
0.24 g MET was suspended in the mixture. In the case of
PCL films, PCL (0.2-0.5 g) was dissolved in 3.2 mL dichlo-
romethane.FilmswerecastintoTeflonplateswithadiameter
of 6.3 cm and dried in an oven at 37-C ± 0.5-C. The solvent
was evaporated, leaving PCL film behind.
Thermal Analysis Studies
Differential scanning calorimetry (DSC) was performed using
a PerkinElmer DSC (Shelton, CT). Film samples of 3 to
5 mg were sealed in aluminum pans and heated from 40-C
to 150-C at a heating rate of 5-C/min under a constant flow
of nitrogen gas. TGAwas performed using a TGA7 thermo-
gravimetric analyzer (PerkinElmer, Norwalk, CT) to deter-
mine the residual solvent level in films.
12 Films were heated
from 25-Ct o1 0 0 -C at a heating rate of 5-C/min.
Morphological Characterization and Particle Size
Measurements of Microparticles Entrapped in the
Prepared Films
Morphological characterization of different prepared films
was studied using scanning electron microscopy (SEM) (Jeol
JSM-6060, Jeol Ltd, Tokyo, Japan). Film samples were gold-
sputtered under vacuum and visualized at an acceleration volt-
age of 80 kV.
The particle size of the microparticles entrapped in different
films was evaluated using an advanced biological microscope
with digital camera at a magnification power of ×100 (Moti-
cam2000USB,2.0megapixels,MoticChinaGroupCo, Ltd,
Xiamen, China). Four hundred particles were measured and
analyzed using Motic Images Advanced software (Version
Table 1. Composition of Different Prepared Formulations and
Melting Point and Enthalpy of MET in Different Films*
Film Code
CH:PCL Ratio
(wt/wt)
Tm
(-C)
Enthalpy
∆H (J/g)
MET — 99.0 107
MCH+MET —— —
Pure LCH† —— —
Pure MCH† —— —
Pure HCH† —— —
PCL† —— —
MCH:PCL 1:0.625 91.9 17.1
LCH:PCL 1:1.25 91.2 27.4
MCH:PCL 1:1.25 90.7 21.7
HCH:PCL 1:1.25 91.4 23.5
MCH:PCL 1:2 90.1 6.00
MCH:PCL 1:2.5 91.2 13.7
2-layered
MCH:PCL
1:0.625 (with a
second layer of pure
2% wt/wt MCH in
1% acetic acid)
92.7 40.0
*MET indicates metronidazole benzoate; CH, chitosan; PCL, poly
(ε-caprolactone); MCH, medium molar mass chitosan; LCH, low molar
mass chitosan; and HCH; high molar mass chitosan.
†Films containing no metronidazole benzoate.
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culated. The polydispersity index (PI), which indicates the
width of particle size distribution and is defined as the rela-
tive standard deviation, was calculated using the following
equation
13:
PI ¼ s=R
−
ð1Þ
where is the mean radius and s is the standard deviation.
Water Absorption Capacity
Circular samples, with a surface of ~2.3 cm
2, of different
films were allowed to swell on the surface of agar plates pre-
p a re dins i m u l a te ds a li v a
14 (2.38 g Na2HPO4,0 . 1 9gK H 2PO4,
and 8 g NaCl per liter of distilled water adjusted with phos-
phoric acid to pH 6.7) and kept in an incubator maintained at
37-C±0 . 5 -C. At preset time intervals (0.25, 0.5, 1, 2, 3, and
4 hours), samples were weighed (wet weight) and then left to
dry for 7 days in a desiccator over anhydrous calcium chloride
at room temperature; then the final constant weights were re-
corded. Water uptake (%) was calculated using the following
equation
15:
Water Uptake ð%Þ¼
ww− wf
wf
  100 ð2Þ
where ww is the wet weight and wf is the final weight. The
swelling of each film was measured at least 3 times.
In Vitro Bioadhesion
The determination of the mucoadhesive force of the prepared
films was performed using an Instron universal testing ma-
chine equipped with a 5-kg load cell (model 8500, digital
control, Instron Co, Canton, MA). Two equal cylindrical me-
tallic supports with a circular surface of 1.7 cm in diameter
were constructed. A circular patch of the film with a surface
area equal to that of the metal support was attached to the
upper support. The external side of a chicken pouch (isolated
from a white hybrid chicken) was attached to the lower sup-
port using cyanoacrylate adhesive. The surfaces of both
the film and the chicken pouch were wetted with simulated
saliva; then the 2 surfaces were brought immediately into
contact with an initial force of 1.5 N for 3 minutes. The
whole experiment was performed at room temperature and a
relative humidity of 50%. The lower support was withdrawn
at a speed of 20 mm/min. During the experiment, the force
was recorded as a function of displacement until the break
point.
16 Data collection and calculation were performed by
dedicated software (Instron series IX, version 8.32.00). The
peak detachment force was used to evaluate the bioadhesive
force of the films.
17 PCL film was used as a negative con-
trol, while pure CH film was used as a positive control. Each
measurement was repeated at least 4 times.
Mechanical Properties
Mechanical properties of the prepared films were evaluated
using an Instron universal testing machine (model 8500 digi-
tal control, Instron) equipped with a 5-kg load cell. Film strips
(20×10 mm) were held between 2 clamps. The thickness of
each strip was measured before each run using an electronic
digital caliper (Ultra-Cal Mark III, Fred V. Fowler Co, Newton,
MA). The force and elongation were measured when the films
broke. The resulting profiles were analyzed using dedicated
software (Instron series IX, version 8.32.00). The following
equations were used to calculate the tensile strength (TS),
18
elongation at break (EB),
14 and elastic modulus (EM)o ft h e
films:
TSðN=mm2Þ¼
Breaking Force
Cross<sectional Area
ð3Þ
EBð%Þ¼
Increase in Length
Original Length
  100
Cross<sectional Area
ð4Þ
EMðN=mm2Þ¼
Force at Corresponding Strain
Cross<sectional Area
  1
Corresponding Strain
ð5Þ
In Vitro Release Studies
Pieces of film (≈1 × 1 cm) equivalent to 5 mg of drug were
placed in stoppered 100-mL conical flasks. The dissolution
medium was used under sink conditions, using 30 mL sim-
ulated saliva kept at 37-C ± 0.5-C. The conical flasks were
shaken in a thermostated horizontal shaker at 50 rpm. At
predetermined intervals, samples of dissolution fluid (2 mL)
were removed and analyzed using UV spectroscopy (Genesys
5 spectrophotometer, Thermo FisherScientificInc,Waltham,
MA) at 310 nm.A UV standard curve was constructed over a
concentration range of 8 to 20 μg/mL. The presence of other
formulation ingredients did not interfere with the spectro-
scopic assay. Each experiment was performed in triplicate.
Release data were kinetically analyzed using Equation 6
19:
Mt
M∞
¼ ktn ð6Þ
 
R
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ta n dM∞ is the total amount of drug released after infinite
time; k denotes a constant; and n is the release exponent in-
dicating the type of drug release mechanism.
Weight Loss Study
Apieceoffilm(1×1cm)wasweighed(Wi) and immersed in
30 mL simulated saliva at 37-C±0 . 5 -C. After 7 hours of
immersion, the piece of film was removed and kept in a de-
siccator over anhydrous calcium chloride for 7 days prior to
being reweighed (Wf). The amount of drug released in the
medium after 7 hours (Wr) was analyzed spectrophotometri-
cally at 310 nm. Each experiment was performed in tripli-
cate. The weight loss was calculated according to the following
equation:
Weight Loss % ¼
ðWi−WrÞ−Wf
Wi
  100 ð7Þ
In Vivo Evaluation of the Selected Formulation
Fourteen healthy adult volunteers (3 males, 11 females), aged
between 20 and 30 years old, participated in the study after
signing informed consents. The study was approved by the
King Saud Ethical Committee and conducted in accordance
with the Declaration of King Saud University. The volunteers
were required to rinse their mouth with water before 2 pieces
of the selected film (each 0.5 × 2 cm) equivalent to 20 mg of
METwereplaced,oneoneachsideoftheirbuccalcavity.The
volunteers were deprived of food and drink during the eval-
uation period. They were asked to record the residence time
ofthe film onthe buccalmucosainthe oralcavity, which was
taken as the time for the film to dislodge completely from the
buccal mucosa. Samples of saliva were collected after 0.25,
0.5,1,2,3,4,5,and6hoursoffilmapplication. (Blanksaliva
samples had been harvested from volunteers before film ap-
plication.)Three hundred microliters ofmethanol were added
to 100-µL saliva samples. The drug was assayed by HPLC.
20
The HPLC system was equipped with a gradient pump (LC-
10AT VP Schimadzu, Kyoto, Japan) and a UV detector (SPD-
10AVP Schimadzu) adjusted at 317 nm. The mobile phase
consisted of a mixture of (25:75 vol:vol) methanol and 0.1M
sodium acetate (pH 4.8). The column used was a reversed
phase Nova-Pak C18 (4.6 × 150 mm with a particle size of
4µm, Waters Co., Milford, MA). Theflow ratewas 1 mL/min.
Standard solutions for the calibration curve were prepared by
spiking 80 µL of human saliva with 20 µL of MET stock
solutions to prepare the following concentrations: 1, 2, 3, 5,
and 8 µg/mL. Methanol (300 µL) was added as a protein pre-
cipitant. The tubes were vortex-mixed for 10 seconds and cen-
trifuged at 6000 rpm for 10 minutes at 5-C. An aliquot of
20 μL of the supernatant of each standard concentration
was injected onto the HPLC column in triplicate.
Statistical Analysis
Data were analyzed by 1-way analysis of variance (ANOVA)
using SPSS statistical package (version 10, 1999, SPSS Inc,
Chicago, IL). Statistical differences yielding P ≤ .05 were
considered significant. Duncan or Tukey’s multiple-comparison
post hoc tests were applied when necessary.
RESULTS AND DISCUSSION
Thermal Analysis Studies
Thermograms recorded from 4-C to 150-C for pure LCH,
MCH, and HCH were similar and showed no thermal events.
Endothermic sharp peaks of pure MET and PCL were re-
corded at 99-C and 57.8-C, respectively. In all prepared film
formulations, PCL showed a broader endotherm at 57.5-C±
1.3-C, as shown in Figures 1 and 2. On the other hand, the
MET endotherm shifted to a lower temperature (91.3-C±
0.8-C) with a smaller melting enthalpy (∆H = 6-40 J/g) rel-
a t i v et op u r ed r u g∆H (107 J/g), as shown in Table 1. This
finding may indicate that the drug existed in the formulations
mostly in an amorphous form. In addition, the presence of
other ingredients in the film may have lowered the chem-
ical potential of the crystalline drug, causing ∆H values to
decrease.
21 TGA revealed that all prepared films had no traces
of dichloromethane.
Figure 1. DSC thermograms of films containing 1:1.25 various
molar mass CH:PCL: (a) LCH:PCL, (b) MCH:PCL, and (c) HCH:
PCL in comparison with (d) MET, (e) PCL, and (f) CH (LCH,
MCH, and HCH). DSC indicates differential scanning calorimetry;
CH, chitosan; PCL, poly(ε-caprolactone); LCH, low molar mass
chitosan; MCH, medium molar mass chitosan; HCH, high molar
mass chitosan; and MET, metronidazole benzoate.
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Measurements of Microparticles Entrapped in the
Prepared Films
All films that contained CH only had a uniform thickness of
140 to 190µm(Table 2) and were transparent. The 2-layered
film was thicker (880 µm) than all 1-layered films (300-
590 µm), as shown in Table 2, and all were opaque.
For all films, PCL microparticles were evident and homoge-
neously dispersed, as shown in the SEM photomicrograph
(Figure 3), and the outer surface of the films was rough.
The mean size of entrapped particles in films containing
1:1.25 LCH:PCL, MCH:PCL, and HCH:PCL was 31 µm
(PI = 0.40), 42 µm (PI = 0.57), and 77 µm (PI = 0.29), re-
spectively, asshowninTable 2. This finding implies that the
molar mass of CH had a noticeable influence on the size of
entrapped PCL particles. This could be due to the increased
Figure 2. DSC thermograms of films containing various ratios
of MCH:PCL: (a) 1:0.625, (b) 1:1.25, (c) 1:2, (d) 1:2.5, and
(e) 2-layered 1:0.625 in comparison with (f) MET, (g) PCL,
and (h) MCH. DSC indicates differential scanning calorimetry;
MCH, medium molar mass chitosan; PCL, poly(ε-caprolactone);
and MET, metronidazole benzoate.
Table 2. Thickness, Particle Size, Polydispersity Index, and Mechanical Properties of Films Containing 1:1.25 Different Molar Mass
Chitosan and Different MCH:PCL wt/wt Ratios (mean ± SD, n = 3)*
Formulations
Film Thickness
(µm)
Particle Size
(µm) PI TS (MPa) % EB (% mm
−2) EM (MPa)
1:1.25
LCH:PCL
300 ± 30 31.0 0.40 0.184 ± 0.01 3.98 ± 0.34 0.89
1:1.25 MCH:PCL 590 ± 20 42.0 0.57 0.503 ± 0.09 5.32 ± 0.83 2.31
1:1.25
HCH:PCL
350 ± 20 77.0 0.29 0.232 ± 0.01 3.97 ± 0.44 1.15
1:0.625 MCH:PCL 590 ± 30 43.8 0.82 1.12 ± 0.11 5.15 ± 0.18 4.82
1:2
MCH:PCL
470 ± 30 51.0 0.71 0.470 ± 0.17 1.74 ± 0.15 5.68
1:2.5
MCH:PCL
440 ± 10 74.5 0.55 0.420 ± 0.05 2.74 ± 0.97 3.59
1:0.625
2-layered
880 ± 20 —— 1.49 ± 0.06 4.51 ± 0.85 5.41
MCH+MET 230 ± 30 —— 1.05 ± 0.19 25.10 ± 4.23 1.84
LCH 190 ± 00 —— 0.819 ± 0.15 25.88 ± 4.89 1.67
MCH 180 ± 10 —— 1.38 ± 0.07 16.24 ± 0.69 4.83
HCH 140 ± 30 —— 1.14 ± 0.19 21.43 ± 3.75 2.83
*MCH indicates medium molar mass chitosan; PCL, poly(ε-caprolactone); PI, polydispersity index; TS, tensile strength; % EB, percentage elongation
at break; EM, elastic modulus; LCH, low molar mass chitosan; HCH; high molar mass chitosan; and MET, metronidazole benzoate.
Figure 3. Scanning electron photomicrograph of one of the
micromatricial MCH:PCL films containing MET. Magnification
 250. MCH indicates medium molar mass chitosan; PCL, poly
(ε-caprolactone); and MET, metronidazole benzoate.
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sequently, the efficiency of homogenization decreased, lead-
ing to the formation of larger PCL particles.
The measured mean particle size of embedded particles in
the film formulations containing different ratios of MCH:
PCL was 43.8 µm (PI = 0.82), 42 µm (PI = 0.57), 51 µm
(PI = 0.71), and 74.5 µm (PI = 0.55) for 1:0.625, 1:1.25,
1:2, and 1:2.5 wt/wt MCH:PCL, respectively, as listed in
Table 2. The PI calculated for all films ranged between 0.55
and 0.82, which indicated a wide particle size distribution.
Itis noticeable thatthe largest particles were measured for the
film that contains the highest ratio of PCL. The high ratio of
PCL may increase the overall viscosity of the homogenized
mixture. Consequently, the efficiency of homogenization may
decrease, leading to the formation of large particles.
Water Absorption Capacity
The swelling results were expressed in terms of percentage
water uptake at 37-C. The effect of 2 main factors, CH molar
mass and MCH:PCL ratio, on the percentage water uptake
was investigated. One-way ANOVA revealed that there was
no statistically significant difference in percentage water up-
take by 1:1.25 wt/wt different molar mass CH:PCL films.
This result was in agreement with Roldo et al,
22 who found
no correlation between the molar mass of CH and its swell-
ing behavior.
Figure 4 shows the swelling behavior of various films con-
taining different ratios (wt/wt) of MCH:PCL in comparison
to pure MCH film and MCH films containing MET. The
water uptake by the prepared films can be ranked as follows:
1:0.625 two-layered ~ 1:0.625 ~ 1:1.25 ~ 1:2 ~ 1:2.5 G
MCH+MET G pure MCH. The results showed that the per-
centage water uptake of the prepared formulations ranged
from 144% to 512%. The equilibrium state was obtained
within about 2 hours. The highest percentage hydration was
obtained for pure CH owing to its hydrophilic nature as a
result of the presence of a free amino group in its structure.
23
The swelling ability of MCH+MET or all films containing
PCL decreased because of the hydrophobic effect exerted by
PCL contents in film. This result was in agreement with what
wasdocumentedbyPeruginietal,
11 who reported a decrease
in film swelling upon addition of the biodegradable polymer
polylactide-co-glycolide to CH film. However, at the exam-
ined ratios of PCL, there was no significant decrease (P 9 .05)
in water uptake as the ratio of PCL increased in the film.
In Vitro Bioadhesion
In this study, the mucoadhesive strength was determined by
measurement of the force of detachment or force of adhesion.
These parameters are the most frequently studied adhesive
properties.
24 Chitosan was documented to produce good ad-
hesion to the mucosal surface, possibly because of the cationic
nature of the polymer, which allows electrostatic interaction
withthe negatively charged mucus inaddition to the physical
entanglement of the polymer chains with the mucus.
25
Plain films containing different molar masses of CH had forces
of adhesion of 10.5 ± 1, 9 ± 0, and 8.4 ± 1 N for LCH, MCH,
and HCH, respectively. Statistical analysis revealed that
there was no significant difference (P 9 .05) in bioadhesion
forcebetweenthefilms.Theseresultswereinagreementwith
Ikinci et al.
26 On the contrary, Roldo et al
22 showed that the
maximum detachment force of MCH was higher than that
of both LCH and HCH.
Similarly,nostatisticallysignificantdifferencewasobserved
in bioadhesion force for films containing 1:1.25 wt/wt var-
ious molar mass CH:PCL and different ratios of MCH:PCL
examined in this study. However, pure MCH and MCH con-
taining MET films showed statistically higher (P G .05) bio-
adhesive force in comparison with films containing different
ratios (wt/wt) of MCH:PCL, as shown in Figure 5. Statistical
analysis revealed that the presence of MET has no signifi-
cantinfluence onthe bioadhesion forceof the prepared MCH
films containing MET.
Mechanical Properties
The tensile testing provides an indication of the strength and
elasticity of the film, which can be reflected by the param-
eters TS,
18 EM, and percentage EB.
14 The effects of CH
molar mass and MCH:PCL ratios (wt/wt) on mechanical prop-
erties of the prepared films were examined.
Figure 4. Percentage water uptake for films containing different
ratios of MCH:PCL in comparison with plain MCH film and
MCH containing MET. MCH indicates medium molar mass
chitosan; PCL, poly(ε-caprolactone); and MET, metronidazole
benzoate. Error bars represent ± SD, n = 3.
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The mechanical properties of various plain CH films and
films containing 1:1.25 wt/wt different molar mass CH:PCL
are listed in Table 2. One-way ANOVA of TS and EM data
of the prepared plain CH films revealed the following rank
order: MCH 9 HCH 9 LCH. Concerning % EB, the 3 films
differed significantly (P ≤ .05); the highest % EB was ob-
tained for LCH, followed by HCH, and finally MCH. These
results were inconsistent with those reported by Sarasam and
Madihally,
21 who found that increasing the molar mass of
CH would cause an increase in the % EB and a decrease in the
TS and EM of the films. This inconsistency in results could be
duetomanyfactors,suchasthedifferenceinCHmolarmassor
the grade and degree of deacetylation of the used chitosan.
Film containing 1:1.25 wt/wt MCH:PCL showed the highest
TS and differed significantly from film containing 1:1.25 wt/wt
LCH:PCL and film containing 1:1.25 wt/wt HCH:PCL. How-
ever, there was no statistically significant difference in TS be-
tween 1:1.25 wt/wt LCH:PCL and 1:1.25 wt/wt HCH:PCL.
These 3 films showed no statistically significant difference in
% EB. On the other hand, the EM of the 3 films was in the
following rank order: MCH:PCL 9 HCH:PCL 9 LCH:PCL.
It was concluded from the above results that the formula-
tion containing 1:1.25 wt/wt MCH:PCL was the strongest
and the most flexible as indicated by the values of % EB
(5.32% mm
−2) and EM (2.31 MPa). Consequently, it was
expected to be suitable for preparing buccal films.
Effect of Different Ratios of Medium Molar Mass
Chitosan:Poly(ε-caprolactone)
Table 2 shows the mechanical properties of various film prep-
arations containing different ratios (wt/wt) of MCH:PCL. One-
way ANOVA followed by Duncan post hoc test revealed
the following order for TS: plain MCH ~ 1:0.625 two-
layered 9 1:0.625 ~ MCH+MET 9 1:1.25 ~ 1:2 ~ 1:2.5. In
other words, there was no direct relationship between TS and
PCL ratio. This finding was in disagreement with Sarasam
and Madihally,
21 who documented that as the ratio of PCL
increased TS also increased. This controversy could be due
to the difference in the method adapted in blending CH with
PCL.Additionally, inthisstudy, PCL was present in the form
of microparticles that could reduce the consistency of the
films and cause discontinuities in their internal structure and
variation in the strength of the film matrix.
27 It was noted that
the highest TS (1.49 MPa) was obtained for 1:0.625 wt/wt
MCH:PCL 2-layered film, indicating a strong film. The in-
creased TS for the 2-layered film could be due to the low
ratioofPCL (inother words,more filmhomogeneity) aswell
as the presence of a second pure MCH layer.
Concerning% EB,Duncanposthoctestrevealedthefollowing
order: 1:0.625 two-layered ~ 1:0.625 ~ 1:1.25 9 1:2 ~ 1:2.5.
All films containing different ratios (wt/wt) of MCH:PCL ex-
cept 1:2 and 1:2.5 could be classified as strong with moderate
%E B ,
28 falling in the range of 4.51% to 5.32% mm
−2.T h e
% EB of 1:2 and 1:2.5 films was very low, having a range
of1.74%to2.74%mm
−2, which indicated brittle films.
27 This
finding can be attributed to the presence of PCL microparti-
cles in higher ratio. On the other hand, the % EB of MCH
+MET (25.1% mm
−2) was significantly higher than that of
all MCH:PCL films. All prepared films had low EM (0.8-
5.68 MPa), as shown in Table 2. Two-layered film containing
1:0.625 wt/wt MCH:PCL had a high EM (5.4 MPa) relative
to almost all other films, indicating relatively high resistance
to deformation under stress.
In summary, the 2-layered film containing 1:0.625 wt/wt
MCH:PCL had the best tensile properties among all prepared
films, as it had the highest TS and relatively high EM and %
EB. Consequently, itcould be considered strong and flexible,
which makes it a good candidate for further studies.
In Vitro Release Studies
TheMETUVstandardcurvewaslinearoveraconcentration
range of 8 to 20 μg/mL, with a determination coefficient
90.9998. Regression analysis of the data of the calibration
curve revealed that the values of the coefficient of regression
(b) were highly significant (P ≤ .0001). Intraday and inter-
day precision and accuracy data were generated and coeffi-
cients of variation were calculated and found to be less than
0.6%. Tests of significance among several regression lines
revealed an insignificant difference between the slopes of
calibration curves (9 replicates) (F8,27 = 1.03). This find-
ing indicated high reproducibility of the standard calibration
curve.
Figure 5. Bioadhesion force of films containing different ratios
of MCH:PCL in comparison with plain MCH film and MCH
containing MET. Similar letters denote no statistically significant
differences, a 9 b. MCH indicates medium molar mass chitosan;
PCL, poly(ε-caprolactone); and MET, metronidazole benzoate.
Error bars represent ± SD, n = 4.
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of MET from the prepared micromatricial film at a CH:PCL
ratio of 1:1.25 wt/wt was examined. Statistical analysis fol-
lowed by Tukey’s test revealed that the rank order of the
amount of MET released from the prepared films was LCH:
PCL ~ MCH:PCL 9 HCH:PCL. This behavior was predict-
able, taking into account the direct relationship between the
molar mass of CH and the viscosity of its solution. By in-
creasing the viscosity of the polymer, the diffusion of the
drug through the formed gel layer into the release medium
was retarded.
29 The high polymer viscosity may also affect
the size of particles formed by reducing the homogenization
efficiency, leading to the formation of larger PCL micro-
particles, as indicated by the particle-size analysis studies.
Therefore, the exposed surface area is reduced and the re-
lease of the entrapped drug is decreased.
Figure 6 shows the effect of various ratios of MCH:PCL
(wt/wt) on the release characteristics of MET from the pre-
pared films. One-way ANOVA followed by Tukey’s test re-
vealed the following rank order: 1:0.625 ~ 1:1.25 ~ 1:2 9
1:2.5. It was obvious that the slowest release was obtained
from films containing the highest ratio of PCL. This result
could be attributed to the higher viscosity of the emulsified
PCL solution used in this formulation. Consequently, rela-
tively large PCL particles were formed (74.5 µm).
The film that consisted of 1:0.625 wt/wt MCH:PCL was
chosen as the formulation because, from an economic point
of view, it had the lowest PCL amount and released ~64% of
thedrugin~7hours.Inaddition, ithadthehighest TSamong
the examined formulations. To improve its adhesive proper-
ties, a second layer of pure MCH was cast onto its surface to
forma2-layeredfilm.ThereleaseofMETfromthe2-layered
film was significantly lower (P ≤ .0001) than that of the cor-
responding 1:0.625 wt/wt MCH:PCL 1-layered film. This re-
sult could be due to the presence of a second layer of CH that
acts as an additional barrier for drug release.
To investigate more precisely the effect of the CH/PCL blend
onthe releaseofMET, theresults wereanalyzed accordingto
the Peppas equation. The calculated kinetic release parame-
ters and determination coefficients (R
2) are summarized in
Table 3.
In general, the values of the determination coefficient ob-
tained after fitting the data to the Peppas equation were high
(≥0.997). The release behavior of MET from the prepared
film formulations was anomalous (non-Fickian), as indicated
by the values of n, which varied from 0.65 to 0.89. The re-
sults of weight loss were consistent withthe predicted release
kinetic behavior. Aweight loss ranging from 43.8%to 58.4%
was observed for various examined film formulations after
7 hours of incubation in simulated saliva, as shown in
Table 3. Since the weight loss indicated the extent of sur-
face erosion and/or polymer degradation, it could be concluded
that the process of polymer degradation, surface erosion, drug
dissolution, and water uptake would occur simultaneously
during the release of MET from films. Similarly, Sarasam
et al
30 reported an initial weight loss in the PCL-CH blend
duetoCH, afterwhichnosignificant changeswereobserved.
These results were consistent with the literature, in which many
authors have generally observed that n departs from Fickian
diffusion for poorly soluble drugs and that the rate-limiting
factor for release is the erosion of the hydrophilic matrix.
31
As a conclusive result of bioadhesion, mechanical proper-
ties, and in vitro release studies for the 2-layered 1:0.625 wt/
wt MCH:PCL film, this film was selected as the formulation
to be evaluated in vivo.
In Vivo Studies
In vivo evaluation of the selected film (2-layered 1:0.625 wt/wt
MCH:PCL) on healthy volunteers revealed that the film did
not cause discomfort, the taste was acceptable, and no severe
salivation was observed. Placement of the film in contact with
cheek mucosa made it possible for the volunteer to speak;
however, food and drink were restricted over the duration of
the experiment to minimize the local clearance of drug from
saliva and the interindividual variability.
The preliminary studies performed to measure in vivo adhesion
time indicated that the 2-layered film containing 1:0.625 wt/wt
MCH:PCL had an in vivo bioadhesion time of 2.15 ± 0.4 hours
compared with about 10 minutes for other films. The great
difference among the adhesion time of films could be due
to their composition, because the 2-layered film containing
1:0.625 wt/wt MCH:PCL had a second pure chitosan layer
that could prolong its adhesion time. It is worth mentioning
Figure 6. Effect of different ratios of MCH:PCL on the release
of MET from the prepared films. MCH indicates medium
molar mass chitosan; PCL, poly(ε-caprolactone); and MET,
metronidazole benzoate. Error bars represent ± SD, n = 4.
AAPS PharmSciTech 2007; 8 (3) Article 75 (http://www.aapspharmscitech.org).
E8that the plain CH layer was the layer that was sticking to the
mucosal surface.
The HPLC standard curve of METwas linear over the calib-
rationrangeof 1 to 8μg/mLwith adetermination coefficient
of 0.9996. Regression analysis of the data from the calibra-
tion curve revealed that the values of the coefficient of re-
gression (b) were highlysignificant (P ≤ .0001). Coefficients
of variation calculated from intraday and interday accuracy
data were less than 7.3%.
Figure 7 shows the salivary profile of METover 6 hours after
buccal application of the selected film. Many interindividual
variations were observed in Cmax (32.9 ± 12.6 µg/mL), Tmax
(3.64 ± 1.9 hours), and area under the salivary drug concen-
tration curve (AUC0-6) (114.99 ± 50 µg·h/mL). This finding
was probably due to the variation in the individuals with
respect to the salivary flow rate, which influences film hy-
dration and clearance of drug in the mouth. The oral ana-
tomy and the individuals’ movement pattern of the tongue
could also have caused variations.
32
The calculated equivalent amount of metronidazole (micro-
biologically active form)
33 released from the selected film
over a period of0.25 to 6.0 hours ranged from 5 to 15 µg/mL.
This range was within and higher than the range of MIC re-
ported for metronidazole against the anaerobic bacteria re-
sponsible for periodontal diseases (≈0.1-8 µg/mL).
34 It is
notable that the amount of drug ingested with swallowed
saliva was not calculated.
In an attempt to correlate the pharmacokinetics (PK) of MET
and its action (pharmacodynamics, PD) on target pathogens
(P gingivalis), the PK/PD relation between Cmax and MIC
was calculated. Considering that the MIC of metronidazole
toward P gingivalis ranged from ≤0.03 to 2 μg/mL,
35 the
calculated Cmax-to-MIC ratios ranged from 10.3 to 685,
which indicated high PD efficacy for MET using a dose of
20 mg.
36
In an attempt to find a correlation between in vitro and in
vivo data, the concentration of drug released in vitro and the
salivary drug concentration in vivo were plotted at the same
time points over 6 hours. A positive linear correlation was
found, with a determination coefficient (R
2)o f0 . 9 6a n d
Pearson coefficient of 0.980 (P G .01). Consequently, sa-
livary drug concentration can be predicted from in vitro re-
lease studies under the adapted experimental conditions using
thefollowingequationwithouttheneedforexpensiveinvivo
studies:
y ¼ 6:1056 þ 10:427 x ð8Þ
where x is the concentration of drug released in vitro
(mg/mL), and y is the salivary drug concentration (µg/mL).
Figure 7. Mean salivary concentration of MET after application
of 2-layered 1:0.625 MCH:PCL film (equivalent to 20 mg of
MET) to 14 healthy volunteers. MET indicates metronidazole
benzoate; MCH indicates medium molar mass chitosan; and
PCL, poly(ε-caprolactone); Error bars represent ± SD, n = 14.
Table 3. Percentage Weight Loss of Films After 7-Hour Incubation in Simulated Saliva and Kinetic Parameters of MET Release From
Different Films Containing MET*
Formulations
% Weight Loss
±S D( n=3 )
Peppas Parameters
Mt/M∞ =k t
n
R
2 kn
1:0.625 MCH:PCL 50.1 ± 1.9 0.9983 0.175 0.6532
1:1.25 LCH:PCL 58.4 ± 1.0 0.9984 0.159 0.7828
1:1.25 MCH:PCL 55.2 ± 0.4 0.9994 0.133 0.8372
1:1.25 HCH:PCL 57.8 ± 1.4 0.9977 0.111 0.8042
1:2 MCH:PCL 50.4 ± 2.1 0.9992 0.162 0.7509
1:2.5 MCH:PCL 47.6 ± 0.3 0.9977 0.108 0.7639
1:0.625 2-layered 43.8 ± 1.9 0.9970 0.098 0.7774
MCH+MET — 0.9984 0.102 0.8927
*Mt indicates amount of drug released in time t; M∞, total amount of drug released after infinite time; K, release constant; n, release exponent
indicating the type of drug release mechanism; MET, metronidazole benzoate; MCH, medium molar mass chitosan; PCL, poly(ε-caprolactone); LCH,
low molar mass chitosan; and HCH, high molar mass chitosan.
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anism controlling the drug release is the same in vitro and in
vivo.
CONCLUSION
The developed mucoadhesive film was satisfactory in terms
of drug release, and mechanical and bioadhesion properties.
In addition, it allowed local delivery of the drug in a concen-
tration higher than the metronidazole MIC against anaerobic
bacteria responsible for periodontal diseases, over 6-hour
periods with high PD efficacy. Moreover, by comparing the
applied dose to the reported systemic dose (20 vs 300 mg), a
remarkablereductionofthesingledrugdosagewasachieved
(~15-fold). In addition, the proposed formulation is not to
be professionally delivered, so it requires little or no patient
compliance for success.
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